A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.

Improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms vs. placebo was reported in a series of pediatric clinical trials of viloxazine extended-release capsules (viloxazine ER; Qelbree™). This post hoc analysis of those studies evaluated the effect of viloxazine ER on learning and s...

Full description

Bibliographic Details
Published in:European Child & Adolescent Psychiatry Vol. 32; no. 3; pp. 491 - 500
Main Authors: Faraone, Stephen V., Gomeni, Roberto, Hull, Joseph T., Busse, Gregory D., Melyan, Zare, Rubin, Jonathan, Nasser, Azmi
Format: clinical trial research tables/charts Journal Article
Published: Springer Nature Mar2023
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162679572&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 162679572
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10188827
        EJ3
      jtl: European Child & Adolescent Psychiatry
      issn: 10188827
      maglogo: N
    pubinfo:
      dt: Mar2023
      vid: 32
      iid: 3
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        162679572
        152668742
        162679572
        162679572
        10.1007/s00787-021-01877-5
        162679572
      ppf: 491
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
      aug:
        au:
          Faraone, Stephen V.
          Gomeni, Roberto
          Hull, Joseph T.
          Busse, Gregory D.
          Melyan, Zare
          Rubin, Jonathan
          Nasser, Azmi
        affil: Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA
      sug:
        subj:
          Antidepressive Agents Therapeutic Use
          Delayed-Action Preparations Therapeutic Use
          Attention Deficit Hyperactivity Disorder Drug Therapy
          Attention Deficit Hyperactivity Disorder Drug Therapy
          Learning Disorders Drug Therapy
          Antidepressive Agents Administration and Dosage
          Clinical Trials
          Post Hoc Analysis
          Human
          Male
          Female
          Adolescence
          Child
          Scales
          Multimethod Studies
          Chi Square Test
          Placebos
          Effect Size
          Data Analysis Software
          Descriptive Statistics
          Funding Source
          Adolescent: 13-18 years
          Child: 6-12 years
          Male
          Female
      ab: Improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms vs. placebo was reported in a series of pediatric clinical trials of viloxazine extended-release capsules (viloxazine ER; Qelbree™). This post hoc analysis of those studies evaluated the effect of viloxazine ER on learning and school problems (LSPs). We used data from four Phase 3 placebo-controlled trials of 100–600 mg/day viloxazine ER (N = 1354; 6–17 years of age). LSPs were evaluated using the School domain of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P-S) and the Learning Problems content scale of the Conners 3rd Edition-Parent Short Form (C3PS-LP) at baseline and end of study (≥ Week 6). ADHD symptoms were assessed weekly using the ADHD Rating Scale 5th Edition. The analyses were performed using the general linear mixed model with participant as a random effect. The responder analyses were performed using the Chi-square test. Viloxazine ER demonstrated significantly greater improvements in WFIRS-P-S (p < 0.0001) and C3PS-LP (p = 0.0113) scores vs. placebo. The response rate for the WFIRS-P-S was significantly greater for viloxazine ER vs. placebo (p = 0.001), and the number needed to treat (NNT) was 10.3 (effect size 0.7). Conversely, response rates for C3PS-LP did not differ between groups (p = 0.9069). In addition to ADHD symptoms improvement demonstrated in previous studies, viloxazine ER significantly reduced LSPs in pediatric subjects with ADHD. The responder analyses and NNT estimates indicate that a substantial number of children and adolescents with ADHD treated with viloxazine ER improved in clinically assessed LSPs.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N